ARROWHEAD PHARMACEUTICALS INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
ARROWHEAD PHARMACEUTICALS INC. - More news...
ARROWHEAD PHARMACEUTICALS INC. - More news...
- Thinking about trading options or stock in General Electric, Roku, CareDx Inc, Arrowhead Pharmaceuticals, or Eli Lilly?
- Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals, Inc. - ARWR Stock Chart Technical Analysis for 09-16-2020
- Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
- Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
- Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
- Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
- Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
- Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
- Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
- Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
- Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
- Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
- Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
- Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
- Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
- Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
- Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
